Articles
New anticancer medicines approved by the EMA in 2025
Published:
2026-07-01
https://doi.org/10.71116/qkf6by41
Authors
View
Keywords
License
Copyright (c) 2026 Miklós Bege, Borbás Anikó (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
How To Cite
Selected Style:
APA
1.
Bege M, Borbás A. New anticancer medicines approved by the EMA in 2025. DRem [Internet]. 2026 Jul. 1 [cited 2026 Jul. 14];2(2). Available from: https://ojs.lib.unideb.hu/de-remediis/article/view/17042
Received 2026-04-17
Accepted 2026-07-01
Published 2026-07-01
Accepted 2026-07-01
Published 2026-07-01
Abstract
Despite the serious progress in the antitumor therapy, cancer did not cease to be one of the leading causes of death in the developed world. Hence still there is high interest for new anticancer agents. In 2025, the EMA approved 104 new medicines, 37 of them containing new active substances. 18 new anticancer medicines were approved (14 new active substances). In this review, we aim to shortly summarize the mechanism of action and use of the new drugs approved by the EMA in the year 2025.
